VGX-1027

Catalog No.C12743 Batch:C1274303

Product Datasheet

Technical Data

Formula	$C_{11}H_{11}NO_3$					
Molecular Weight	205.21	**CAS No.**	6501-72-0			
Solubility (25°C)*	In vitro	DMSO	41 mg/mL (199.79 mM)			
		Ethanol	41 mg/mL (199.79 mM)			
		Water	Insoluble			
	In vivo (Add solvents to the product individually and in order)	Oral Administration	Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Capsid Bio tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped at 2-8°C for storage purposes.)

Preparing Stock Solutions

Concentration \ Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.8731 mL	24.3653 mL	48.7306 mL
5 mM	0.9746 mL	4.8731 mL	9.7461 mL
10 mM	0.4873 mL	2.4365 mL	4.8731 mL
50 mM	0.0975 mL	0.4873 mL	0.9746 mL

Biological Activity

Description	VGX-1027 (GIT 27) is an orally active **immunomodulator**. Phase 1.
In vitro	VGX-1027 significantly inhibits both IL-1β/IFN-γ-induced TNF-α and nitrite accumulation, and causes a significant increase in cell survival by interfering with the cytotoxic effects of the cytokines. [1] This compound inhibits both proliferation of enterobacterial antigen-reactive CD4+CD25− T cells in vitro. [2]
In vivo	VGX-1027 prevents development of spontaneous type 1 diabetes in NOD Mice and counteracts accelerated diabetogenesis induced by cyclophosphamide challenge or adoptive transfer of diabetogenic spleen cells in NOD Mice. This compound also reduces clinical signs of MLD-STZ-induced diabetes and suppresses pathohistological changes of pancreas. [1] It suppresses the development of clinical, histological and immunological signs of DNBS-induced colitis in CD1 mice. [2] In NZB/NZW F1 model of systemic lupus erythematosus (SLE), this chemical ameliorates the course of the disease with higher percent survival and improved clinical and histopathological signs. [3]

Protocol (from reference)

Animal Study:[1]

- **Animal Models**
  NOD Mice with MLD-STZ-induced diabetes.
- **Dosages**
  20 mg/kg b.wt. i.p. and 100 mg/kg b.wt. p.o.
- **Administration**
  i.p. or p.o.

References

https://pubmed.ncbi.nlm.nih.gov/17148780/

[3] Fagone P, et al. Immunology. 2014, doi: 10.1111/imm.12267.

RETURN POLICY

Capsid Bio's Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING & STORAGE

Capsid Bio products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Capsid Bio Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Capsid Bio products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

EU Headquarters
Gajeva ulica 28, HR-10000 Zagreb, Croatia

US Headquarters
12222 Merit Dr STE 130 Dallas, Texas, 75251

UK Headquarters
121 ABILITY HOUSE, BROOKER ROAD, EN9 1JH, ESSEX

Orders: Sales@capsidbio.com
Enquiries: info@capsidbio.com
www.capsidbio.com